ArticleToxins2024
Sensitive Aflatoxin M1 Detection in Milk by ELISA: Investigation of Different Assay Configurations.
Article in Toxins, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Anti-aflatoxigenic effect of Lactobacillus rhamnosus and its synbiotic combination of chitosan/ZnO in milk.AMB Express · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Aflatoxin M1 (AFM1) exposure through dairy products is associated with adverse health effects, including hepatotoxicity and carcinogenicity. Therefore, the AFM1 presence in milk and dairy products is strictly regulated. In this context, the current work focuses on the investigation of different competitive enzyme immunoassay configurations for the determination of AFM1 in milk with high sensitivity and short assay duration. Amongst the configurations tested, the one based on incubation of the anti-AFM1 specific antibody along with the calibrators/samples and a biotinylated conjugate of AFM1 with bovine serum albumin (BSA) in microwells coated with a secondary antibody provided a six-fold lower detection limit than the configuration involving immobilized AFM1-BSA conjugate and liquid phase antibody. The detection limit achieved was 5.0 pg/mL, with a dynamic range of up to 2.0 ng/mL. The assay was repeatable with intra- and inter-assay coefficients of variations lower than 3.2% and 6.5%, respectively, and accurate with recovery values from 87.5 to 108%. Moreover, the assay was completed in 1.5 h. The excellent analytical characteristics and short analysis time make the proposed assay suitable for use by the food industry. Furthermore, the proposed configuration could be employed to enhance the detection sensitivity of competitive immunoassays for other low-molecular-weight analytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.